172
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      WAO Guideline for the Management of Hereditary Angioedema

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers. For this reason we convened a group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus. Since both consensus and evidence grading were adhered to the document meets criteria as a guideline. The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists.

          Related collections

          Most cited references134

          • Record: found
          • Abstract: found
          • Article: not found

          Hereditary angioedema: new findings concerning symptoms, affected organs, and course.

          Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Our aim was to examine a temporal and spatial pattern of the edema episodes by evaluating the long-term course of hereditary angioedema in order to establish a specific swelling pattern. Data were generated from 221 patients with C1 inhibitor deficiency by asking them about symptoms they experienced during their edema episodes. Documentation was accomplished through the use of standardized questionnaires. A total of 131110 edema episodes were observed. Clinical symptoms started at a mean age of 11.2 (SD 7.7) years. During the following cumulative 5736 years, only 370 (6.5%) symptom-free years occurred. Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease. The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes. The per-patient analysis and the per-episode analysis revealed markedly discrepant results. On average, women had a more severe course of the disease than men. Patients with early onset of clinical symptoms were affected more severely than those with late onset. The described swelling pattern is specific for HAE and allows a tentative diagnosis based on clinical symptoms and the course of the disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

            Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

              Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Objective To update the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (circa 2010). Methods The Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May 15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed at the meeting and then circulated for review. Results This manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema that resulted from that conference. Conclusions Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical trials and then evidence-based guidelines and standards for HAE disease management.
                Bookmark

                Author and article information

                Contributors
                Journal
                World Allergy Organ J
                World Allergy Organ J
                The World Allergy Organization Journal
                World Allergy Organization
                1939-4551
                December 2012
                15 December 2012
                : 5
                : 12
                : 182-199
                Affiliations
                [1 ]Department of Medicine, Pediatrics and Graduate Studies, Penn State University, Hershey, PA
                [2 ]Center for Pediatric and Juvenile Medicine, J.W. Goethe University, Frankfurt/(Main), Germany
                [3 ]Department of Dermatology, Johannes Gutenberg University Mainz, Mainz, Germany
                [4 ]Departments of Medicine and Pediatrics, University of Calgary, Calgary, Canada
                [5 ]HAEi, Orsay, France
                [6 ]3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
                [7 ]Outpatient Group of Recurrent Infections and Laboratory of Immunology, Faculty of Medicine ABC; Department of Dermatology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil
                [8 ]Department of Medicine, Campbelltown Hospital, University of Western Sydney, Sydney, New South Wales, Australia
                [9 ]Allergy, Asthma and Immunology Associates of Tampa Bay, University of South Florida, Tampa, FL
                [10 ]Department of Immunology, Barts Health NHS Trust, London, United Kingdom
                [11 ]Allergy and Asthma Specialists, Dallas, TX
                [12 ]Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Berlin, Germany
                [13 ]Department of Medicine, University of Alberta, Edmonton, Canada
                [14 ]Division of Allergy, Dept. of Pediatrics, Nippon Medical School, Tokyo, Japan
                [15 ]President WAO, Professor of Medicine, Department of Medicine, University of California San Diego and San Diego VA Healthcare
                Article
                1939-4551-5-12-182
                10.1097/WOX.0b013e318279affa
                3651186
                23282420
                edeeedbe-f78e-4705-b2cb-2cf69118a857
                Copyright ©2012 World Allergy Organization; licensee BioMed Central Ltd.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                WAO Guideline

                Immunology
                hereditary angioedema,guidelines,hae,therapy,management,diagnosis,medications,international
                Immunology
                hereditary angioedema, guidelines, hae, therapy, management, diagnosis, medications, international

                Comments

                Comment on this article